EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors

Xiao-Mei Chen, Qing-Qing Hao, Christophe Pannecouque, Erik De Clercq, Shuai Wang, Fen-Er Chen

Acta Pharmaceutica Sinica B · 2025-08 · 15 (8) · 4115-4136

DOI: 10.1016/j.apsb.2025.06.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-08. Verfasst von Xiao-Mei Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fudan University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AIDSAnti-resistance potencyBioisosterismDiarylpyrimidinesHIV-1NNRTIsOral bioavailabilitySafety

Autor:innen und Institutionen

  • Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
  • Rega Institute for Medical Research, KU Leuven, Herestraat 49, Leuven B-3000, Belgium.
  • Engineering Center of Catalysis and Synthesis for Chiral Molecules, Department of Chemistry, Fudan University, Shanghai 200433, China.
  • Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs, Shanghai 200433, China.
  • Institute of Flow Chemistry and Engineering, School of Chemistry and Materials, Jiangxi Normal University, Nanchang 330022, China.

Förderung

  • Fudan University
  • National Natural Science Foundation of China

Zitieren

APA

Chen, X. M., Hao, Q. Q., Pannecouque, C., De Clercq, E., Wang, S., & Chen, F. E. (2025). Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Acta Pharmaceutica Sinica B, 15(8), 4115-4136. https://doi.org/10.1016/j.apsb.2025.06.016

Vancouver

Chen XM, Hao QQ, Pannecouque C, De Clercq E, Wang S, Chen FE. Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Acta Pharmaceutica Sinica B. 2025;15(8):4115-4136. doi:10.1016/j.apsb.2025.06.016

BibTeX
@article{Chen2025,
  author = {Chen, Xiao-Mei and Hao, Qing-Qing and Pannecouque, Christophe and De Clercq, Erik and Wang, Shuai and Chen, Fen-Er},
  title = {Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {4115--4136},
  doi = {10.1016/j.apsb.2025.06.016}
}
Kostenlos starten →